Guardant Health stock hits 52-week high at 68.01 USD

Guardant Health Inc. (GH) stock reached a new 52-week high, touching 68.01 USD. According to InvestingPro data, the company maintains strong financial health with a current ratio of 3.71, indicating robust liquidity. The company’s market capitalization now stands at $8.35 billion. This milestone reflects a significant upward trend over the past year, with the company’s stock experiencing an impressive 221.37% increase. The surge in Guardant Health’s stock price highlights investor confidence and market optimism surrounding the company’s performance and future prospects. With revenue growth of 28.74% in the last twelve months, the company shows strong operational momentum. Get deeper insights into GH’s valuation and growth potential with a comprehensive Pro Research Report, available exclusively on InvestingPro. This achievement comes amid a broader context of growth and innovation within the healthcare sector, further solidifying Guardant Health’s position as a key player in the industry.

In other recent news, Guardant Health, Inc. has received approval from the U.S. Food and Drug Administration for its Guardant360 CDx blood test. This test will serve as a companion diagnostic for Eli Lilly’s breast cancer drug Inluriyo, specifically targeting patients with ESR1 mutations. Meanwhile, several investment firms have updated their ratings and price targets for Guardant Health following its recent Investor Day. Bernstein has reiterated an Outperform rating with a $60 price target, and JPMorgan continues to hold an Overweight rating, citing updated financial targets for 2028 that project approximately $2.2 billion in revenue. Guggenheim has increased its price target to $67, maintaining a Buy rating, influenced by Guardant Health’s product launches. Similarly, TD Cowen has raised its price target to $72, also maintaining a Buy rating, despite noting a sector-wide decline in diagnostics stocks. These developments reflect Guardant Health’s ongoing efforts to expand its diagnostic capabilities and financial projections.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.